November 2010
Pharmaceutical Representative;Nov2010, Vol. 40 Issue 11, p10
The article reports on the approval of Boehringer Ingelheim Pharmaceutical Inc.'s Pradaxa capsules by the U.S. Food and Drug Administration (FDA), the drug is used for the prevention of blood clots and stroke in patients with abnormal heart rhythm.


Related Articles

  • FDA actions.  // Neurology Alert;Dec2010 Supplement, p2 

    This section presents an update on drug approvals and other related issues made by the U.S. Food and Drug Administration (FDA). It details the approval given by the FDA for fingolimod, a drug used for the treatment of relapsing forms of multiple sclerosis. Information is also given on the...

  • FDA OKs Boehringer Ingelheim atrial fibrillation pill. Soule, Alexander // Fairfield County Business Journal;11/1/2010, Vol. 49 Issue 44, p11 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on Pradaxa, formulated in capsules by Boehringer Ingelheim Pharmaceuticals Inc. to prevent stroke in patients with abnormal heart rhythm in Fairfield County, Connecticut in 2010.

  • New products.  // Drug Topics;Dec2014, Vol. 158 Issue 12, p77 

    The article offers information on several U.S. Food & Drug Administration (FDA)-approved drugs that are now available in the market. Boehringer Ingelheim Pharmaceuticals Inc.'s nintedanib (Ofev), approved by FDA in October 2014 to treat idiopathic pulmonary fibrosis (IPF), is now available in...

  • FDA approves Boehringer's asthma treatment. Brody, Danielle // Fairfield County Business Journal;9/21/2015, Vol. 51 Issue 38, p15 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the Spiriva Respimat maintenance asthma treatment drug of Boehringer Ingelheim Pharmaceuticals Inc.

  • FDA Approves One-Pill, Once-Daily Viramune(r) XR(tm) (nevirapine) Extended- Release Tablets for Use in Combination With Other Antiretroviral Agents for Treatment of HIV-1 Infection in Adults.  // Biomedical Market Newsletter;5/5/2011, p807 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the use of Viramune XR extended- release tablets from Boehringer Ingelheim Pharmaceuticals Inc. for use with other antiretroviral agents for treatment of HIV-1 Infection in adults. The approved drug offers patients...

  • FDA panel recommends approval of tipranavir. Roehr, Bob // Bay Area Reporter;5/26/2005, Vol. 35 Issue 21, p16 

    Reports on the United States Food and Drug Administration's pending approval of the protease inhibitor tipranavir (trade name Aptivus) for use in salvage therapy for HIV. Advisory committee's concern and reservations to recommend that approval; Boehringer Ingelheim Pharmaceutical Inc.'s...

  • Boehringer Ingelheim offers new heart tabs. Doran, Ryan // Fairfield County Business Journal;10/26/2009, Vol. 48 Issue 43, p11 

    The article reports on the approval of Micardis Tablets 80 milligrams, a new heart disease-related tablet, manufactured by Boehringer Ingelheim Pharmaceutical in Ridgefield, Connecticut. It indicates that the U.S. Food and Drug Administration has approved the new drug which is an angiotensin II...

  • FDA Update.  // Renal & Urology News;Nov2009, Vol. 8 Issue 11, p50 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The U.S. Food and Drugs Administration (FDA) has approved the Votrient for the treatment of advance renal cell carcinoma (RCC). The FDA has granted a marketing clearance for Colcrys, a new colchincine formulation...

  • Boehringer Ingelheim wins FDA approval for Parkinson's drug.  // PharmaWatch: CNS;May2010, Vol. 9 Issue 5, p4 

    The article discusses the approval of Boehringer Ingelheim Pharmaceuticals' Mirapex ER tablets by the U.S. Food & Drug Administration (FDA) for the treatment of Parkinson's disease (PD). It states that a clinical study has supported the approval of Mirapex ER by FDA and that patients with...


Read the Article


Sign out of this library

Other Topics